Related Experiment Videos
How does liver dysfunction influence serum CA 19-9 in pancreatic cancer?
D Basso1, C Fabris, G Del Favero
1Istituti di Medicina Interna (Cattedra di Malattie Apparato Digerente), Università degli Studi di Padova, Italy.
The Italian Journal of Gastroenterology
|February 1, 1990
Summary
Serum CA 19-9 is a useful marker for pancreatic cancer. Liver damage and cholestasis can elevate CA 19-9 levels, potentially impacting diagnostic accuracy.
Area of Science:
- Oncology
- Gastroenterology
- Clinical Chemistry
Background:
- Carbohydrate antigen 19-9 (CA 19-9) is a tumor marker often used in pancreatic cancer diagnosis.
- The influence of hepatic factors on CA 19-9 levels requires further investigation.
Purpose of the Study:
- To evaluate the impact of hepatic factors on serum CA 19-9 levels in patients with pancreatic cancer.
- To assess the sensitivity, specificity, and accuracy of CA 19-9 for pancreatic malignancy.
Main Methods:
- Serum CA 19-9 levels were measured in control subjects and patients with pancreatic cancer, chronic pancreatitis, and extra-pancreatic diseases.
- Patients were categorized into groups with and without anatomical liver damage.
- Correlations between CA 19-9 and liver function tests (ALT, ALP, total bilirubin) were analyzed using multiple regression.
Main Results:
- CA 19-9 demonstrated a sensitivity of 74%, specificity of 83%, and accuracy of 57% for pancreatic malignancy.
- Patients with anatomical liver damage exhibited higher CA 19-9 values.
- Significant correlations between CA 19-9 and liver enzymes/bilirubin were observed in patients without liver damage.
Conclusions:
- CA 19-9 is a valuable marker for pancreatic cancer, but its interpretation should consider liver health.
- Anatomical liver damage and extra-hepatic cholestasis may falsely elevate CA 19-9 levels.
- Hepatic factors can influence CA 19-9, potentially affecting its diagnostic utility.